Cargando…
Secondary CNS myeloma with remission after systemic CNS-penetrating agents
BACKGROUND: CNS myeloma is a rare manifestation of multiple myeloma and is often associated with a dismal prognosis; however, cases are increasing in frequency as overall survival improves for MM. There is currently no standardized treatment for CNS myeloma; however, different chemotherapy and radio...
Autores principales: | Fernandez, Luis G, Oyon, Daniel Eduardo, Gondi, Vinai, Grimm, Sean, Khan, Osaama H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307102/ https://www.ncbi.nlm.nih.gov/pubmed/35892045 http://dx.doi.org/10.1093/noajnl/vdac106 |
Ejemplares similares
-
Building Team Medicine in the Management of CNS Metastases
por: Baskaran, Archit B., et al.
Publicado: (2023) -
Using methylation profiling to diagnose systemic metastases of pleomorphic xanthoastrocytoma
por: Kam, Kwok-Ling, et al.
Publicado: (2019) -
The value of bone marrow biopsy for staging of patients with primary CNS lymphoma
por: Margold, Michelle, et al.
Publicado: (2021) -
Phase II study of intravenous etoposide in patients with relapsed ependymoma (CNS 2001 04)
por: Apps, John R, et al.
Publicado: (2022) -
Phase I dose-escalation, safety, and CNS pharmacokinetic study of dexanabinol in patients with brain cancer
por: Juarez, Tiffany M, et al.
Publicado: (2021)